Neovascularization, Corneal, CL-related Workup

1. Dixon JM. Corneal vascularization due to corneal contact lenses: the clinical picture. Trans Am Ophthalmol Soc. 1967. 65:333-40. [QxMD MEDLINE Link].

2. Dixon JM, Lawaczec E. Corneal vascularization due to contact lenses. Arch Ophthalmol. 1963. 69:106-9.

3. Papas EB. The role of hypoxia in the limbal vascular response to soft contact lens wear. Eye Contact Lens. 2003 Jan. 29 (1 Suppl):S72-4; discussion S83-4, S192-4. [QxMD MEDLINE Link].

4. Chen W, Xu Z, Jiang H, Zhou J, Wang L, Wang J. Altered Bulbar Conjunctival Microcirculation in Response to Contact Lens Wear. Eye Contact Lens. 2017 Mar. 43 (2):95-99. [QxMD MEDLINE Link]. [Full Text].

5. Alipour F, Khaheshi S, Soleimanzadeh M, Heidarzadeh S, Heydarzadeh S. Contact Lens-related Complications: A Review. J Ophthalmic Vis Res. 2017 Apr-Jun. 12 (2):193-204. [QxMD MEDLINE Link]. [Full Text].

6. Chan WK, Weissman BA. Corneal pannus associated with contact lens wear. Am J Ophthalmol. 1996 May. 121(5):540-6. [QxMD MEDLINE Link].

7. Cogan DG. Vascularization of the cornea. Its experimental induction by small lesions and a new theory of its pathogenesis. Arch Ophthalmol. 1949. 41:406-416.

8. Cogan DG. Corneal vascularization. Investigative Ophthalmology and Vis. 1962. (1): 2:253-61.

9. Ashton N, Cook C. Mechanisms of corneal neovascularization. Brit J Ophthal. 1953. 37:193-209.

10. Madigan MC, Penfold PL, Holden BA, Billson FA. Ultrastructural features of contact lens-induced deep corneal neovascularization and associated stromal leukocytes. Cornea. 1990 Apr. 9(2):144-51. [QxMD MEDLINE Link].

11. Groden LR, Cassel GH, Laibson PR. The effect of corneal trephination on neovascularization. Ophthalmic Surg. 1983 Nov. 14(11):954-6. [QxMD MEDLINE Link].

12. Imre G. The role of increased lactic acid concentration in neovascularizations. Acta Morphol Hung. 1984. 32(2):97-103. [QxMD MEDLINE Link].

13. Fromer CH, Klintworth GK. An evaluation of the role of leukocytes in the pathogenesis of experimentally induced corneal vascularization. Am J Pathol. 1975 Jun. 79(3):537-54. [QxMD MEDLINE Link].

14. Fromer CH, Klintworth GK. An evaluation of the role of leukocytes in the pathogenesis of experimentally induced corneal vascularization. III. Studies related to the vasoproliferative capability of polymorphonuclear leukocytes and lymphocytes. Am J Pathol. 1976 Jan. 82(1):157-70. [QxMD MEDLINE Link].

15. Koch AE, Polverini PJ, Leibovich SJ. Induction of neovascularization by activated human monocytes. J Leukoc Biol. 1986 Feb. 39(2):233-8. [QxMD MEDLINE Link].

16. Klintworth GK. Corneal Angiogenesis. New York: Springer-Verlag; 1991. 1-30.

17. Brennan NA, Coles ML, Comstock TL, Levy B. A 1-year prospective clinical trial of balafilcon a (PureVision) silicone-hydrogel contact lenses used on a 30-day continuous wear schedule. Ophthalmology. 2002 Jun. 109 (6):1172-7. [QxMD MEDLINE Link].

18. Sweeney DF. Have silicone hydrogel lenses eliminated hypoxia?. Eye Contact Lens. 2013 Jan. 39(1):53-60. [QxMD MEDLINE Link].

19. Forister J, Forister EF, Yeung KK, Chung MY, Ye P, Tsai A, et al. Weissman BA. Prevalence of common ocular complications associated with contact lens wear: The UCLA contact lens complication study. Vis Opt Sci (In preparation).

20. Lee SY, Kim YH, Johnson D, Mondino BJ, Weissman BA. Contact lens complications in an urgent-care population: the University of California, Los Angeles, contact lens study. Eye Contact Lens. 2012 Jan. 38 (1):49-52. [QxMD MEDLINE Link].

21. Donnenfeld ED, Ingraham H, Perry HD, Imundo M, Goldberg LP. Contact lens-related deep stromal intracorneal hemorrhage. Ophthalmology. 1991 Dec. 98(12):1793-6. [QxMD MEDLINE Link].

22. Filipec M, Hycl J, Kraus H. [Does vascularization and the graft diameter affect the rejection reaction in corneal transplantation?]. Cesk Oftalmol. 1994 Feb. 50(1):13-7. [QxMD MEDLINE Link].

23. Faraj LA, Said DG, Al-Aqaba M, Otri AM, Dua HS. Clinical evaluation and characterisation of corneal vascularisation. Br J Ophthalmol. 2015 Jul 10. 1-8. [QxMD MEDLINE Link].

24. Abdelfattah NS, Amgad M, Zayed AA, Salem H, Elkhanany AE, Hussein H, et al. Clinical correlates of common corneal neovascular diseases: a literature review. Int J Ophthalmol. 2015. 8 (1):182-93. [QxMD MEDLINE Link].

25. Foulks GN, Steffanson E, Hamilton RC. Regression of corneal vascularization during silicone contact lens wear and the relationship to contact lens-induced anterior chamber hypoxia. Cornea. 1987. 65:6-60.

26. Qian CX, Bahar I, Levinger E, Rootman D. Combined use of superficial keratectomy and subconjunctival bevacizumab injection for corneal neovascularization. Cornea. 2008 Oct. 27(9):1090-2. [QxMD MEDLINE Link].

27. Gupta D, Illingworth C. Treatments for corneal neovascularization: a review. Cornea. 2011 Aug. 30(8):927-38. [QxMD MEDLINE Link].

28. Zaki AA, Farid SF. Subconjunctival bevacizumab for corneal neovascularization. Acta Ophthalmol. 2010 Dec. 88(8):868-71. [QxMD MEDLINE Link].

29. Chang JH, Garg NK, Lunde E, Han KY, Jain S, Azar DT. Corneal neovascularization: an anti-VEGF therapy review. Surv Ophthalmol. 2012 Sep. 57 (5):415-29. [QxMD MEDLINE Link].

30. Motarjemizadeh Q, Aidenloo NS, Sepehri S. A comparative study of different concentrations of topical bevacizumab on the recurrence rate of excised primary pterygium: a short-term follow-up study. Int Ophthalmol. 2016 Feb. 36 (1):63-71. [QxMD MEDLINE Link].

31. Chen WL, Chen YM, Chu HS, Lin CT, Chow LP, Chen CT, et al. Mechanisms controlling the effects of bevacizumab (avastin) on the inhibition of early but not late formed corneal neovascularization. PLoS One. 2014. 9 (4):e94205. [QxMD MEDLINE Link].

32. Benelli U, Bocci G, Danesi R, Lepri A, Bernardini N, Bianchi F. The heparan sulfate suleparoide inhibits rat corneal angiogenesis and in vitro neovascularization. Exp Eye Res. 1998 Aug. 67(2):133-42. [QxMD MEDLINE Link].

33. Crum R, Szabo S, Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science. 1985 Dec 20. 230(4732):1375-8. [QxMD MEDLINE Link].

34. Lipman RM, Epstein RJ, Hendricks RL. Suppression of corneal neovascularization with cyclosporine. Arch Ophthalmol. 1992 Mar. 110(3):405-7. [QxMD MEDLINE Link].

35. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994 Apr 26. 91(9):4082-5. [QxMD MEDLINE Link].

36. Bian F, Zhang MC, Zhu Y. Inhibitory effect of curcumin on corneal neovascularization in vitro and in vivo. Ophthalmologica. 2008. 222(3):178-86. [QxMD MEDLINE Link].

37. Wong AL, Weissman BA, Mondino BJ. Bilateral corneal neovascularization and opacification associated with unmonitored contact lens wear. Am J Ophthalmol. 2003 Nov. 136(5):957-8. [QxMD MEDLINE Link].

38. Maguire MB. Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Opthal. 1974. 101:1536-1547.

39. Sawa M, Awazu K, Takahashi T, et al. Application of femtosecond ultrashort pulse laser to photodynamic therapy mediated by indocyanine green. Br J Ophthalmol. 2004 Jun. 88(6):826-31. [QxMD MEDLINE Link].

40. Holzer MP, Solomon KD, Vroman DT, et al. Photodynamic therapy with verteporfin in a rabbit model of corneal neovascularization. Invest Ophthalmol Vis Sci. 2003 Jul. 44(7):2954-8. [QxMD MEDLINE Link].

41. Sugisaki K, Usui T, Nishiyama N, Jang WD, Yanagi Y, Yamagami S, et al. Photodynamic therapy for corneal neovascularization using polymeric micelles encapsulating dendrimer porphyrins. Invest Ophthalmol Vis Sci. 2008 Mar. 49 (3):894-9. [QxMD MEDLINE Link].

42. Caffery BE, Josephson JE. Corneal vascularization. Optom Clin. 1995. 4(3):19-29. [QxMD MEDLINE Link].

43. Chen P, Yin H, Wang Y, Wang Y, Xie L. Inhibition of VEGF expression and corneal neovascularization by shRNA targeting HIF-1a in a mouse model of closed eye contact lens wear. Mol Vis. 2012. 18:864-73. [QxMD MEDLINE Link].

44. Grohe RM, Lebow KA. Vascularized limbal keratitis. Int Contact Lens Clinics. 1989. 16:197-209.

45. Jouseen AM, Druse FE, Volcker HE, et al. Topical application of methotrexate for inhibition of corneal angiogenesis. Graefes Arch Clin Exp Ophthalmol. 1999. 238:920-7.

46. Verbey NL, van Haeringen NJ, de Jong PT. Modulation of immunogenic keratitis in rabbits by topical administration of inhibitors of liposygenase and cyclooxygenase. Curr Eye Res. 1998. 7:361-8.

Barry A Weissman, OD, PhD, FAAO Retired Professor of Optometry, Southern California College of Optometry at Marshall B Ketchum University; Professor Emeritus of Ophthalmology, Stein Eye Institute, University of California, Los Angeles, David Geffen School of Medicine

Barry A Weissman, OD, PhD, FAAO is a member of the following medical societies: American Academy of Optometry, American Optometric Association, California Optometric Society, International Society for Contact Lens Research

Disclosure: Nothing to disclose.

Karen K Yeung, OD, FAAO Senior Optometrist, UCLA Arthur Ashe Student Health and Wellness Center; Clinical Assistant Professor, College of Optometry, Western University of Health Sciences

Karen K Yeung, OD, FAAO is a member of the following medical societies: American Academy of Optometry

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Christopher J Rapuano, MD Professor, Department of Ophthalmology, Sidney Kimmel Medical College of Thomas Jefferson University; Director of the Cornea Service, Wills Eye Hospital

Christopher J Rapuano, MD is a member of the following medical societies: American Academy of Ophthalmology, American Ophthalmological Society, American Society of Cataract and Refractive Surgery, Contact Lens Association of Ophthalmologists, Cornea Society, Eye Bank Association of America, International Society of Refractive Surgery

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: AAO; OMIC; American Society of Ophthalmic Trauma (ASOT); Avellino, Baxis; Bio-Tissue; Celularity; Dompe; Emmecell; Glaukos; Kala; Oyster Point; Sun Ophthalmics; Tarsus; TearLab<br/>Serve(d) as a speaker or a member of a speakers bureau for: Glaukos; Dompe; Bio-Tissue<br/>Received research grant from: Glaukos<br/>Received income in an amount equal to or greater than $250 from: AAO; OMIC; Baxis; Bio-Tissue; Cellularity; Dompe; Glaukos; Kala; Sun Ophthalmics; TearLab<br/>stock options for: RPS, Fount Bio.

Hampton Roy, Sr, MD † Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Hampton Roy, Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, Pan-American Association of Ophthalmology

Disclosure: Nothing to disclose.

Andrew W Lawton, MD Neuro-Ophthalmology, Ochsner Health Services

Andrew W Lawton, MD is a member of the following medical societies: American Academy of Ophthalmology, Arkansas Medical Society, Southern Medical Association

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article